AMENDMENT NO. 1 TO THE DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • March 11th, 2020 • Pfenex Inc. • Pharmaceutical preparations
This Amendment No. 1 to the Development and License Agreement (“Amendment”) is entered into as of October 7, 2019 (“Amendment Effective Date”) by and between Pfenex Inc., a Delaware corporation (“Pfenex” or “Party”) and Alvogen Malta (Out-Licensing) Ltd., a Maltese corporation (“Alvogen” or “Party”, and together with Pfenex, the “Parties”)
TRANSITION AGREEMENT AND LIMITED RELEASETransition Agreement and Limited Release • March 11th, 2020 • Pfenex Inc. • Pharmaceutical preparations • California
This Transition Agreement and Limited Release (“Limited Release”) is made by and between Susan A. Knudson (“Executive”) and Pfenex Inc. (the “Company”) (collectively, Executive and the Company referred to as the “Parties” or individually referred to as a “Party”).
